Clinical trials: Ovarian Neoplasm Epithelial, open to volunteers
Advanced Unresectable, Metastatic
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
This is a multicenter, open-label, Phase 1/2 master protocol evaluating autologous dual-target CAR-T cell therapy in adults with advanced solid cancers.
- Trial name
- SELECT-2CAR (NCT07523529)
- Testing
- Autologous dual-target CAR-T cells selected from the predefined target library., Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Beijing Biotech
Prostate Cancer, Breast Cancer
Measuring Oncological Value of Exercise and Statin
The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to…
- Conditions
- Prostate Cancer, Breast Cancer, Kidney Cancer, Ovarian Cancer
- Trial name
- MOVES (NCT05796973)
- Testing
- Guided physical exercise, Atorvastatin, Independent exercise
- Where
- Finland
- Volunteers
- 240 people
- Sponsor
- Tampere University Hospital
Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer
EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma
MDG1015 is a third generation TCR-T therapy product targeting NY-ESO-1/LAGE-1a armored and enhanced by the PD1-41BB costimulatory switch protein (CSP).
- Conditions
- Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer, Soft Tissue Sarcoma (STS), Myxoid Liposarcoma
- Trial name
- EPITOME-1015-I (NCT06748872)
- Testing
- Lymphodepletion, TCR-T cells (MDG1015)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Medigene AG
Metastatic Solid Tumors, Stage 4 Cancer
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sarah Nanotechnology System.
- Trial name
- NCT07224464
- Testing
- The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors.
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- New Phase Ltd.
Ovarian Epithelial Cancer
Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer
Ovarian cancer is among the top five primary causes of cancer-related mortality in women. Most ovarian malignant tumours originate from epithelial cells The majority of patients typically have advanced-stage tumours at diagnosis.
- Trial name
- NCT06404671
- Testing
- Delayed interval cytoreductive surgery (DICS), Early interval cytoreductive surgery (EICS)
- Where
- Egypt
- Volunteers
- 250 people
- Sponsor
- Alexandria University
Carcinoma, Endometrioid, Fertility Preservation
Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer
Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different…
- Trial name
- NCT06468215
- Testing
- Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Peking University People's Hospital
Breast Cancer, Endometrial Cancer
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway…
- Conditions
- Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma
- Trial name
- NCT07109726
- Testing
- TER-2013, Fulvestrant injection
- Where
- 20 sites in United States, Portugal and 2 more
- Volunteers
- 205 people
- Sponsor
- Terremoto Biosciences Inc.
Ovarian Cancer, Pancreas Cancer
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma.
- Conditions
- Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
- Trial name
- NCT06582017
- Testing
- QXL138AM Injection every 2 weeks by IV Infusion
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nammi Therapeutics Inc
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
- Conditions
- Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05902988
- Testing
- VLS-1488
- Where
- 14 sites in United States
- Volunteers
- 200 people
- Sponsor
- Volastra Therapeutics, Inc.
Ovarian Cancer (OvCa)
A Prospective Observational Study of Senaparib in the Treatment of Epithelial Ovarian Cancer
Ovarian cancer is one of the most fatal malignant tumors that threaten women's health. The incidence rate is the third place among the female reproductive system malignant tumors, and the mortality rate ranks the first in…
- Trial name
- RESO (NCT07586449)
- Testing
- Senaparib capsules(20mg)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Zhejiang Cancer Hospital
Ovarian Cancer
Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)
Ovarian cancer was mostly diagnosed at late stage (III/IV) with high rate of recurrence after first line of therapy by optimal cytoreductive sugery and 6cycle of TP chemotherapy.
- Trial name
- NCT04520074
- Testing
- Etoposide, Cyclophosphamide, Carboplatin/Cisplatin
- Where
- China
- Volunteers
- 590 people
- Sponsor
- Fudan University
Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum
Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
This study evaluates the safety, tolerability, and preliminary anti-tumor activity of EB-DUALNK, a dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy, in adults with recurrent or refractory epithelial…
- Trial name
- EB-DUALNK-OV (NCT07589543)
- Testing
- EB-DUALNK, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Beijing Biotech
Amyloidosis, Basal Cell Carcinoma
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and…
- Conditions
- Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma
- Trial name
- NCT07285044
- Testing
- Cancer Therapeutic Procedure, Questionnaire Administration
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
Advanced Solid Tumors
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
- Trial name
- NCT05914116
- Testing
- DB-1311, Lopinavir and Ritonavir Tablets, itraconazole
- Where
- 107 sites in United States, Australia and 2 more
- Volunteers
- 862 people
- Sponsor
- DualityBio Inc.
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant
- Trial name
- NCT06890338
- Testing
- Carboplatin, Mirvetuximab Soravtansine, Bevacizumab
- Where
- 73 sites in United States
- Volunteers
- 140 people
- Sponsor
- AbbVie
Cancer, Sarcoma
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide/fludarabine (CY/FLU) and supported with low-dose IL-15…
- Conditions
- Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- EBNK-ST-001 (NCT07410676)
- Testing
- EBNK-001 + IL-15 + Pembrolizumab
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Essen Biotech
Acute Leukemia, Adenomatous Polyposis
Familial Investigations of Childhood Cancer Predisposition
NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll.
- Conditions
- Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML
- Trial name
- SJFAMILY (NCT03050268)
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- St. Jude Children's Research Hospital
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy…
- Conditions
- Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
- Trial name
- NCT04104776
- Testing
- Tulmimetostat, Enzalutamide
- Where
- 80 sites in United States, France and 5 more
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Epithelial Ovarian Cancer
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
This study will evaluate the efficacy, safety and tolerability of Torvutatug samrotecan (torvu-sam) in combination with bevacizumab compared with bevacizumab monotherapy as first line maintenance treatment in patients with…
- Trial name
- TREVI-OC-02 (NCT07851025)
- Testing
- Torvutatug samrotecan, Bevacizumab
- Where
- 186 sites in United States, Argentina and 22 more
- Volunteers
- 950 people
- Sponsor
- AstraZeneca